Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

William Fusselman (NPI 1659356228)

Field	Value
Entity Type	Individual
Organization	William Fusselman
Address	202 10th Street Se
City	Cedar Rapids
State	IA
ZIP	52403
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	December 7, 2005

Payer Source	Total Paid
Medicare	$1.3M
Medicaid	$0

Key Findings

WILLIAM FUSSELMAN is listed as a Hematology & Oncology Physician with an NPI enumerated 2005-12-07 (~21 years ago) and $1.3M in lifetime Medicare revenue. There is no Medicaid billing on file for this provider, so the practice is effectively single‑payer in the available dataset and financially exposed to Medicare reimbursement patterns rather than state Medicaid dynamics. The top three Medicare codes drive a concentrated share of income, accounting for 68.1% of total Medicare revenue.

Revenue concentration is pronounced: J9271 (pembrolizumab) alone accounts for $645K revenue (51.1% of this provider's total Medicare revenue), making it the dominant revenue driver for this clinician. With the precomputed top-3 concentration at 68.1%, the practice appears highly dependent on a small number of high-cost oncology drug administrations, which implies sensitivity to changes in drug pricing, utilization, or payer coverage for those agents.

The clinical/service mix is consistent with an infusion-centric oncology practice: major drug administration codes include J9271 (pembrolizumab, $645K), J0897 (denosumab, $140.8K), and Q5119 (rituximab‑pvvr, $56.1K), while chemotherapy administration codes such as 96413 (497 claims, $46.7K) and add‑ons like 96417 ($5K) and 96415 ($4K) further reflect on‑site infusion capability. This pattern indicates active systemic therapy delivery rather than a purely consultative practice, with both immunotherapy and supportive bone‑targeted agents forming the revenue backbone.

Evaluation-and-management utilization is above typical national levels for office visits: 99214 generated 801 claims and $73.7K revenue (5.8%) and ranks #19499 of 479517 providers nationally (96th percentile; notably above typical national volume for this code), while 99213 and 99215 also appear in high national percentiles (99213 ranks in the 95th percentile; 99215 in the 91th percentile). High E/M volumes suggest a sizable established patient panel and ongoing follow‑up activity that complements infusion services, reinforcing a regular ambulatory oncology practice footprint.

Imaging and diagnostics support active cancer management rather than incidental use: 78815 (PET/CT) produced $71.7K (5.7% of Medicare revenue) and A9552 (FDG dose) contributed $11.2K, indicating routine use of PET imaging for staging or treatment monitoring. These imaging and lab lines (e.g., 80053 CMP $15.4K; 85025 CBC $13.2K) combined with advanced infusion codes show integrated diagnostic and therapeutic workflows typical of oncology clinics that coordinate imaging, labs, and systemic therapy.

Competitive standing is mixed: although J9271 is the largest revenue source, its national rank is moderate (#687 of 1841 providers; 62th percentile; typical, unremarkable volume for this code), so this provider is not a national outlier for pembrolizumab volume despite high local revenue concentration. Other drug codes show varying positions—J0897 ranks #1515 of 10057 (85th percentile; typical, unremarkable volume) and Q5119 ranks #93 of 335 (72th percentile; typical, unremarkable volume)—indicating solid but not dominant participation nationally for these oncology drugs.

Operational footprint is consistent with in‑office procedural and clinical capacity: high counts for venipuncture (36415, 1.2K claims, $9.4K) and infusion‑related administration (96375, 718 claims, $7.9K; 96365, 133 claims, $6K) together with frequent lab panels (80053, 1.5K claims) point to workflows that manage infusion prep, monitoring, and post‑infusion care on site. The presence of vaccine codes (91322 $4.3K; 90662 $3.5K) is secondary but suggests routine preventive services are also provided in the clinic setting.

Payer mix and financial risk: with $1.3M concentrated solely in Medicare and no Medicaid billing on file, this provider’s public‑payer exposure is effectively single‑payer in the available data. Combined with the fact that the top three Medicare codes account for 68.1% of revenue, the practice’s revenue profile is both concentrated by payer and by therapy type, implying sensitivity to Medicare policy or coverage changes affecting high‑cost oncology infusions.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

66 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	15,000	$40	$645K
J0897	Injection, denosumab, 1 mg	8,280	$20	$140.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	800	$90	$73.7K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	70	$1,090	$71.7K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	2,550	$20	$56.1K
J1439	Injection, ferric carboxymaltose, 1 mg	48,750	$1	$48.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	500	$90	$46.7K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	580	$60	$35.4K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	190	$130	$25.8K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	1,540	$10	$15.4K

Showing 1–10 of 66

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 66 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

William Fusselman — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

66 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	18	30	17,200	$40	$902.3K
J0897	24	190	1,920	$20	$74.1K
Q5119	1	10	2,550	$20	$56.8K
J1439	3	10	41,250	$1	$39.7K
96413	13	80	210	$90	$24K
78815	27	90	40	$270	$20.4K
91322	422	580	80	$140	$15.2K
99214	164	4,690	100	$70	$14.4K
74177	176	210	130	$80	$12.5K
A9552	6	20	30	$140	$8.4K

Showing 1–10 of 66

Related Providers

Other providers that share a Tax Identification Number (TIN) with William Fusselman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Physicians' Clinic Of Iowa, PC	IA	Surgery Physician	$0	$4.9M
Bogdan Cherascu	IA	Rheumatology Physician	$2.4M	$0
Vijay Aluri	IA	Rheumatology Physician	$2M	$0
Bharat Jenigiri	IA	Medical Oncology Physician	$1.5M	$0
Rasa Buntinas	IA	Hematology & Oncology Physician	$1.1M	$0
Ritu Munjal	IA	Family Medicine Physician	$1M	$0
Harinder Singh	IA	Rheumatology Physician	$789.3K	$0
Jonathan Rippentrop	IA	Urology Physician	$487.4K	$0
Thomas Richardson	IA	Urology Physician	$373K	$0
Sandeep Munjal	IA	Adult Reconstructive Orthopaedic Surgery Physician	$322K	$0

Nearby Providers

Other providers in the same ZIP code as William Fusselman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mercy Medical Center	IA	General Acute Care Hospital	$0	$26.4M
Eastern Iowa Health Center	IA	Family Medicine Physician	$0	$24.5M
Eastern Iowa Health Center	IA	Family Medicine Physician	$0	$18.5M
Eastern Iowa Health Center	IA	General Practice Dentistry	$0	$14.4M
Linn County Emergency Medicine PC	IA	Emergency Medicine Physician	$0	$9.8M
C R Iv Service Inc	IA	Home Infusion Therapy Pharmacy	$0	$5.8M
Mercy Medical Center	IA	Cardiovascular Disease Physician	$0	$5.1M
C R Pharmacy Service Inc	IA	Oxygen Equipment & Supplies (DME)	$0	$2.4M
Eastern Iowa Sleep Center, LLC	IA	Sleep Disorder Diagnostic Clinic/Center	$243.7K	$1.6M
Rapids Dental	IA	Dental Clinic/Center	$0	$1.7M

William Fusselman — Billing Profile & Reimbursement Data

Sign up for William Fusselman — Billing Profile & Reimbursement Data policy alerts

William Fusselman — Billing Profile & Reimbursement Data

Sign up for William Fusselman — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References